Evidence map›Paper›PMID 34885173›Full record

ArticleCancers2021

An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation.

Jeovanis Gil, Melinda Rezeli, Elmar G Lutz, Yonghyo Kim, Yutaka Sugihara, Johan Malm, Yevgeniy R Semenov, Kun-Hsing Yu, Nga Nguyen, Guihong Wan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 5 countries.

Jeovanis GilDivision of Oncology, Department of Clinical Sciences, Lund University, 222 42 Lund, Sweden.ORCID 0000-0003-3601-3893
Melinda RezeliClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, 222 42 Lund, Sweden.
Elmar G LutzDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 1085 Budapest, Hungary.
Yonghyo KimDivision of Oncology, Department of Clinical Sciences, Lund University, 222 42 Lund, Sweden.ORCID 0000-0002-4447-9864
Yutaka SugiharaDivision of Oncology, Department of Clinical Sciences, Lund University, 222 42 Lund, Sweden.
Johan MalmSection for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden.ORCID 0000-0002-9365-7313
Yevgeniy R SemenovDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02110, USA.ORCID 0000-0002-7387-3094
Kun-Hsing YuDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
Nga NguyenDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02110, USA.ORCID 0000-0003-2935-3603
Guihong WanDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02110, USA.
Lajos V KeményDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 1085 Budapest, Hungary.
Sarolta KárpátiDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 1085 Budapest, Hungary.
István Balázs NémethDepartment of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary.
György Marko-VargaDivision of Oncology, Department of Clinical Sciences, Lund University, 222 42 Lund, Sweden.
Lund University · SEHarvard University · USSemmelweis University · HUTokyo Medical University · JPUniversity of Szeged · HU

Funding

Robust, Generalizable, and Fair Machine Learning Models for BiomedicineR35GM142879 · NIGMS · HARVARD MEDICAL SCHOOL · PI YU, KUN-HSING · 2021 to 2025
$2.4M
Berta Kamprad Foundation MelanomaHungarian Academy of Sciences János Bolyai Research ScholarshipHungarian Academy of Sciences K125509Hungarian National Research, Development and Innovation Office OTKA FK138696NIGMS NIH HHS R35GM142879
6 · The paper itself

Abstract

Melanoma in advanced stages is one of the most aggressive tumors and the deadliest of skin cancers. To date, the histopathological staging focuses on tumor thickness, and clinical staging is a major estimate of the clinical behavior of primary melanoma. Here we report on an observational study with in-depth molecular profiling at the protein level including post-translational modifications (PTMs) on eleven primary tumors from melanoma patients. Global proteomics, phosphoproteomics, and acetylomics were performed on each sample. We observed an up-regulation of key mitochondrial functions, including the mitochondrial translation machinery and the down-regulation of structural proteins involved in cell adhesion, the cytoskeleton organization, and epidermis development, which dictates the progression of the disease. Additionally, the PTM level pathways related to RNA processing and transport, as well as chromatin organization, were dysregulated in relation to the progression of melanoma. Most of the pathways dysregulated in this cohort were enriched in genes differentially expressed at the transcript level when similar groups are compared or metastasis to primary melanomas. At the genome level, we found significant differences in the mutation profiles between metastatic and primary melanomas. Our findings also highlighted sex-related differences in the molecular profiles. Remarkably, primary melanomas in women showed higher levels of antigen processing and presentation, and activation of the immune system response. Our results provide novel insights, relevant for developing personalized precision treatments for melanoma patients.

Indexed as

antigen presentationdisease progressionlysine acetylation stoichiometrymalignant melanomaMHC complexmitochondriamitochondrial translationprimary melanomaproteogenomicsPTMs

Identifiers

PMID34885173
PMCPMC8657311
OpenAlexW3215249267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.